Multi Targeted CAR-T Cell Therapies for B-Cell Malignancies

被引：145
作者：
Shah, Nirav N. [1 ]
Maatman, Theresa [2 ]
Hari, Parameswaran [1 ]
Johnson, Bryon [1 ]
机构：
[1] Med Coll Wisconsin, Div Hematol & Oncol, Milwaukee, WI 53226 USA
[2] Med Coll Wisconsin, Dept Med, Milwaukee, WI 53226 USA
来源：
FRONTIERS IN ONCOLOGY | 2019年 / 9卷
关键词：
CAR-T; antigen escape; B-cell NHL; B-cell ALL; immunotherapy; ANTIGEN ESCAPE; RECEPTOR; EFFICACY; RESISTANCE; LEUKEMIA;
D O I：
10.3389/fonc.2019.00146
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
Chimeric antigen receptor (CAR) modified T cell therapy has revolutionized the treatment of relapsed and refractory hematological malignancies. Through targeting of the CD19 antigen on B cells durable remissions have been achieved in patients with B cell non-Hodgkin lymphoma and acute lymphoblastic lymphoma. Despite impressive responses, multiple escape mechanisms to evade CAR-T cell therapy have been identified, among which the most common is loss of the target antigen. In this review we will highlight outcomes to date with CD19 CAR-T cell therapy, describe the current limitations of single targeted CAR-T therapies, review identified tumor escape mechanisms, and lastly discuss novel strategies to overcome resistance via multi-targeted CAR-T cells.
引用
收藏
页数：7
相关论文
共 50 条
[31]   Overcoming Antigen Escape and T-Cell Exhaustion in CAR-T Therapy for Leukemia [J].
Bartoszewska, Elzbieta ;
Tota, Maciej ;
Kisielewska, Monika ;
Skowron, Izabela ;
Sebastianka, Kamil ;
Stefaniak, Oliwia ;
Molik, Klaudia ;
Rubin, Jakub ;
Kraska, Karolina ;
Choromanska, Anna .
CELLS, 2024, 13 (18)
[32]   Accelerating CAR-T Cell Therapies with Small-Molecule Inhibitors [J].
Mestermann, Katrin ;
Garitano-Trojaola, Andoni ;
Hudecek, Michael .
BIODRUGS, 2025, 39 (01) :33-51
[33]   γδ T cells in immunotherapies for B-cell malignancies [J].
Rimailho, Lea ;
Faria, Carla ;
Domagala, Marcin ;
Laurent, Camille ;
Bezombes, Christine ;
Poupot, Mary .
FRONTIERS IN IMMUNOLOGY, 2023, 14
[34]   Clinical evidence of immunogenicity of CAR-T cell therapies and its implication in the clinical development of CAR-T drug products [J].
Alfar, Hammodah R. ;
Chen, Cecil ;
Lachacz, Eric ;
Tang, Weifeng ;
Zhang, Yuqian .
FRONTIERS IN IMMUNOLOGY, 2025, 16
[35]   B7-H3-targeted CAR-T cell therapy for solid tumors [J].
Li, Guangfei ;
Wang, Haopeng ;
Wu, Haitao ;
Chen, Jian .
INTERNATIONAL REVIEWS OF IMMUNOLOGY, 2022, 41 (06) :625-637
[36]   Current state of CAR-T therapy for T-cell malignancies [J].
Luo, Liangkui ;
Zhou, Xuan ;
Zhou, Lijuan ;
Liang, Zhao ;
Yang, Jilong ;
Tu, Sanfang ;
Li, Yuhua .
THERAPEUTIC ADVANCES IN HEMATOLOGY, 2022, 13
[37]   Current state of CAR-T therapy for T-cell malignancies [J].
Luo, Liangkui ;
Zhou, Xuan ;
Zhou, Lijuan ;
Liang, Zhao ;
Yang, Jilong ;
Tu, Sanfang ;
Li, Yuhua .
THERAPEUTIC ADVANCES IN HEMATOLOGY, 2022, 13
[38]   Mesothelin-targeted CAR-T cell therapy for solid tumors [J].
Klampatsa, Astero ;
Dimou, Vivian ;
Albelda, Steven M. .
EXPERT OPINION ON BIOLOGICAL THERAPY, 2021, 21 (04) :473-486
[39]   Resistance and recurrence of malignancies after CAR-T cell therapy [J].
Zeng, Wanying ;
Zhang, Pumin .
EXPERIMENTAL CELL RESEARCH, 2022, 410 (02)
[40]   The Role of the Tumor Microenvironment in T-Cell Redirecting Therapies of Large B-Cell Lymphoma: Lessons Learned from CAR-T to Bispecific Antibodies [J].
Lepik, Kirill V. ;
Markelov, Vladislav V. .
CANCERS, 2025, 17 (02)
12345